Find what you need in the Fundación Valle del Lili

Are you looking for a medical service, a specialty, a healthcare professional, or information about appointments and programs?
Use our smart search engine to easily access everything that the Fundación Valle del Lili.

Services for you

Study of nemtabrutinib (MK-1026) versus a comparator (investigator's choice, ibrutinib or acalabrutinib) in first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) – 06136559

Study ID: 06136559

Randomized phase 3 study to compare nemtabrutinib versus a comparator (investigator's choice, ibrutinib or acalabrutinib) in untreated participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (BELLWAVE-011)

About the study:

 

This study is evaluating nemtabrutinib (MK-1026) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Nemtabrutinib is an investigational medicine. It has not been approved to treat CLL or SLL. The study will compare nemtabrutinib with two treatments for CLL and SLL: ibrutinib and acalabrutinib. Ibrutinib and acalabrutinib have been approved in some countries for the treatment of CLL and SLL. However, they may not be approved in your country for your type of cancer. This study is being conducted with the following objectives: to evaluate the safety of nemtabrutinib compared to ibrutinib or acalabrutinib, and to determine how well nemtabrutinib works compared to ibrutinib or acalabrutinib. You can participate in this study if you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated before.

Total length

Target audiences

Ages: 18 - N/A years
Sex: All

Location

Merck Sharp & Dohme LLC

Associated diseases

  • Lymphocytic leukemia
  • Oncology

Request an appointment via WhatsApp
Request a call
Medical Directory
Check results
Contact